全世界2型糖尿病市场于2023年将达460亿美元

制药与医疗保健参谋公司Decision Resources日前发布一份新陈诉：2型糖尿发病病率的不停升高、对于可以或许持久有用节制病情药物的高度未满意需求的市场有很年夜的促成，跟着美国、日本、欧洲5年夜重要市场（法国、德国、意年夜利、西班牙、英国）2型糖尿病市场高速增加，整个市场也会从2013年的260亿美元增加至2023年的460亿美元。

作者： 年夜康健派编纂来历： 中国IDC圈2016-07-19 17:10:12

制药与医疗保健参谋公司Decision Resources日前发布一份新陈诉：2型糖尿发病病率的不停升高、对于可以或许持久有用节制病情药物的高度未满意需求的市场有很年夜的促成，跟着美国、日本、欧洲5年夜重要市场（法国、德国、意年夜利、西班牙、英国）2型糖尿病市场高速增加，整个市场也会从2013年的260亿美元增加至2023年的460亿美元。

详情请间接看原文：

英文原文：Continued Uptake of Branded Therapies Will Drive the Type 2 Diabetes Market to Increase from 美金26 Billion in 2013 to 美金47 Billion in 2023

SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group

BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ Decision Resources Group finds that as physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs. As the robust type 2 diabetes pipeline increases the range of therapeutic options available to physicians, the o�����APPverall type 2 diabetes market within the G7 (United States, France, Germany, Italy, Spain, United Kingdom and Japan) is set for rapid expansion, with growth from sales of over 美金26 billion in 2013 to 美金47 billion in 2023.

Other key findings from the Pharmacor advisory service entitled Type 2 Diabetes:

SGLT-2 inhibitors: The recently launched SGLT-2 inhibitors are experiencing rapid uptake in the major markets, despite known associations with genital mycotic and urinary tract infections; the first-to-market entrants canagliflozin (Johnson Johnson s Invokana) and dapagliflozin (AstraZeneca s Farxiga/Forxiga) are set to garner significant sales.GLP-1 receptor agonists: The GLP-1 receptor agonist class is also set for significant growth during the forecast period, with the emergence of a number of once-weekly agents set for considerable uptake. As the only once-weekly agent to thus far demonstrate non-inferiority to the market-leading liraglutide (Novo Nordisk s Victoza), dulaglutide (Eli Lilly s Trulicity) is set to garner significant uptake.Increasingly stringent reimbursement: In response to the increasing cost burden of type 2 diabetes, payer and reimbursement agencies are becoming increasingly stringent with regard to reimbursable therapies. Payers are increasingly restricting the number of options available to physicians, particularly for drug classes with multiple therapy options, such as the DPP-IV inhibitors.Biosimilar insulins: The emergence of biosimilar insulins during the forecast period, in particular Eli Lilly/Boehringer Ingelheim s biosimilar insulin glargine (Basaglar/Abasria), are set to enjoy considerable uptake in response to payer concerns over the escalating costs of existing insulin formulations. However, the cost-savings associated with biosimilars are less than those associated with generic small molecules.Co妹妹ents from Decision Resources Group Analyst Eamonn O Connor, Ph.D.:

Initial uptake of the SGLT-2 inhibitors has been stronger than previously anticipated, with uptake of first-to-market canagliflozin in the United States closely mirroring sales of sitagliptin (Merck s Januvia), the market-leading DPP-IV inhibitor with over 美金4 billion in annual sales in 2013. With the majority of emerging novel therapies representing me-too therapeutic options with few truly distinguishing features from earlier-to-market entries, the type 2 diabetes market may be set to witness class-specific price wars for the first time. The GLP-1 receptor agonist class appears to be the most vulnerable, with albiglutide (GlaxoSmithKline s Tanzeum/Eperzan) launching at a considerable discount to the market-leading GLP-1 agonist liraglutide.

一杯米：互联网医疗第一媒体